Shandong Jincheng Pharmaceutical Group Co., Ltd Stock

Equities

300233

CNE100001500

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-15 pm EDT 5-day change 1st Jan Change
17.5 CNY -1.74% Intraday chart for Shandong Jincheng Pharmaceutical Group Co., Ltd -5.61% +5.04%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2022 3.51B 485M Sales 2023 3.54B 490M Capitalization 6.34B 877M
Net income 2022 273M 37.78M Net income 2023 175M 24.22M EV / Sales 2022 2.43 x
Net cash position 2022 208M 28.81M Net cash position 2023 471M 65.11M EV / Sales 2023 1.66 x
P/E ratio 2022
32.1 x
P/E ratio 2023
37 x
Employees 3,806
Yield 2022
0.66%
Yield 2023
1.2%
Free-Float 69.23%
More Fundamentals * Assessed data
Dynamic Chart
Chinese Drug Regulator Gives Thumbs Up to Jincheng Pharmaceutical Unit's Application to Raise Cefadroxil Dry Suspension's Dosage MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023, Payable on May 8, 2024 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on February 2, 2024. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback announced on February 2, 2024, has closed with 4,543,000 shares, representing 1.18% for CNY 55 million. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 70 million worth of its shares. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd authorizes a Buyback Plan. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jincheng Pharmaceutical Gets License to Produce E-Cigarette Nicotine MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Directorate Appointments CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Cash Dividend for the Year 2022 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for 2022 CI
More news
1 day-1.74%
1 week-5.61%
Current month-7.01%
1 month+18.16%
3 months+21.28%
6 months-2.83%
Current year+5.04%
More quotes
1 week
17.33
Extreme 17.33
18.71
1 month
14.89
Extreme 14.89
20.50
Current year
10.83
Extreme 10.83
20.50
1 year
10.83
Extreme 10.83
21.60
3 years
10.83
Extreme 10.83
44.98
5 years
10.83
Extreme 10.83
44.98
10 years
9.99
Extreme 9.99
59.83
More quotes
Managers TitleAgeSince
President 52 08-01-31
Director of Finance/CFO 48 -
Chief Tech/Sci/R&D Officer 60 03-12-31
Members of the board TitleAgeSince
Chairman 48 04-06-30
President 52 08-01-31
Director/Board Member 51 08-02-15
More insiders
Date Price Change Volume
24-05-16 17.5 -1.74% 10,253,410
24-05-15 17.81 -0.78% 9,230,000
24-05-14 17.95 +0.50% 12,891,100
24-05-13 17.86 -2.24% 18,766,200
24-05-10 18.27 -1.46% 25,592,250

End-of-day quote Shenzhen S.E., May 15, 2024

More quotes
Shandong Jincheng Pharmaceutical Group Co Ltd, formerly Shandong Jincheng Pharmaceutical Co Ltd, is a China-based company mainly engaged in pharmaceutical manufacturing. The Company operates primarily through three segments. Intermediates segment mainly produces cephalosporin side chain pharmaceutical intermediates and other pharmaceutical and chemical products. Preparation segment focuses on the antimicrobial field and women's health technology. Specialty Active Pharmaceutical Ingredients segment includes biological specialty active pharmaceutical ingredients and chemical active pharmaceutical ingredients. The Company also operates other businesses.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300233 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW